Slide 1: First Quarter 2026 Financial and Operating Results
First Quarter 2026 Financial and Operating Results May 4, 2026 © Copyright 2026 Krystal Biotech, Inc. All rights reserved.
Slide 2: Forward Looking Statements and Disclosures
Forward Looking Statements and Disclosures This presentation and the discussion contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934
Slide 3: Building a Profitable, Fully Integrated, Global Leader in Rare Disease
Building a Profitable, Fully Integrated, Global Leader in Rare Disease Global VYJUVEK Net Revenue: Over $846M Since Launch US$ millions $116.4 $96.0 $97.8 $107.1 ✓ Global Footprint Over 300 5+ $91.1 $88.2 $83.8 $70.3 Krystal employees Countries $45.3 $42.1 ✓ In-House Manufacturing $8.6 175K+ sq ft 3
Slide 4: FDA Grants Platform Designations for Three Pipeline Products
FDA Grants Platform Designations for Three Pipeline Products ✓ Reduced regulatory redundancy KB801 for neurotropic keratitis ✓ Faster development timelines KB407 KB111 ✓ Streamlined review process for for cystic fibrosis Hailey-Hailey disease ✓ Compounding regulatory advantage FDA, United States Foo
Slide 5: Strong Execution in Overseas Markets
Strong Execution in Overseas Markets Launched Markets* Over 140 ▪ $28.9M in net revenue in Europe and Japan Estimated DEB Patients with VYJUVEK Prescriptions Across Germany, France*, and Japan ▪ Pricing negotiation decisions expected in 2H 2026 in Germany and 2027 in France ▪ Launch in Italy and Spa
Slide 6: Building on Our Leadership Position in the United States
Building on Our Leadership Position in the United States ▪ $87.5M in net revenue in the U.S. ▪ Strong sales force execution is driving demand , community reach, and patient starts Over 695 ▪ Over 60 new prescribers 1Q 2026 Reimbursement Approvals ▪ Over 570 unique prescribers since launch for VYJUVE
Slide 7: KB801 and KB803 Registrational Study Readouts Expected Later This Year
KB801 and KB803 Registrational Study Readouts Expected Later This Year KB803 for Treatment and Prevention of Corneal Abrasions in DEB Fully Enrolled April 2026 16 DEB Patients Enrolled Top-Line Data Expected 4Q 2026 Registrational IOLITE Study Design KB801 for Neurotrophic Keratitis KB803 Three Time
Slide 8: Many More Clinical Milestones on the Horizon
Many More Clinical Milestones on the Horizon KB407 ▪ Initiating open-label study to evaluate safety of repeat dose KB407 in CF for CF patients, expecting to dose first patient later this month Platform technology ▪ Expect to complete enrollment in 2Q 2026 and report data in 4Q 2026 ✓ designation gra
Slide 9: First Quarter 2026 Financial Highlights
First Quarter 2026 Financial Highlights Cash and investments: $1.017 billion as of March 31, 2026 Diluted EPS: $1.83 Three Months Ended March 31 2026 2025 Product revenue, net $116.4M $88.2M Cost of goods sold $6.3M $5.0M Gross margin 95% 94% R&D expenses $15.3M $14.3M SG&A expenses $41.0M $32.6M St
Slide 10: Upcoming Milestones in 2026
Upcoming Milestones in 2026 ▪ Global VYJUVEK expansion with launches in Italy and Spain ▪ Two registrational study readouts in ophthalmology ▪ KB803 for corneal abrasions in DEB patients ▪ KB801 for neurotrophic keratitis ▪ Repeat dose study results on the path towards registrational studies and rea
Slide 11: Developing Genetic Medicines to Treat Diseases with High Unmet Medical Needs
Developing Genetic Medicines to Treat Diseases with High Unmet Medical Needs © Copyright 2026 Krystal Biotech, Inc. All rights reserved.